Liposarcoma — Trials · CancerIndex

Clinical trials

Registered studies

136 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 50
Recruiting: 25
Ph III recruiting: 2
Growth YoY: —
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (22)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05905341	Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.	withdrawn	Phase 1	0	PfizerINDUSTRY	0	Nov 8, 2023	clinicaltrials
NCT03880123	Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma	withdrawn	Phase 1	0	Matthew InghamOTHER	1	Nov 27, 2020	clinicaltrials